Contributors 4408

CONTRIBUTORS

Over the past year, extraordinary events and market forces have redefined many sectors of the medical device industry. But with the changes of 2007 already beginning to recede in the rearview mirror, medtech executives are rapidly turning their attention toward the challenges of the coming year.

Market Analysis

To keep their companies on track in 2008, medtech company leaders will need to be watching for the signs of coming industry change. In "The Medtech Marketplace in 2008", five industry experts provide insights into the trends driving key medical device sectors. James Cavuoto, editor of Neurotech Reports (San Francisco), explores the emerging sector of neurotechnology, which is just beginning to capitalize on potential therapeutic applications. Cavuoto can be reached at 415/ 546-1259 or via e-mail at [email protected]. Venkat Rajan, a medical device industry analyst at Frost & Sullivan (San Antonio, TX), takes a look at the cardiology sector, for which 2008 represents an opportunity to renew confidence and reinvigorate sales in waning product segments. Rajan can be reached at 210/247-2427 or via e-mail at [email protected]. Shara Rosen, senior analyst for Kalorama Information (New York City), examines the in vitro diagnostics sector, which promises to continue its journey toward personalized medicine following a significant restructuring of its competitive landscape in 2007. Rosen can be reached at 514/421-2705 or via e-mail at [email protected]. Anthony G. Viscogliosi, principal of Viscogliosi Bros. LLC (New York City), provides an analysis of the orthopedics sector, which enters 2008 with a record level of private equity under its belt. Viscogliosi can be reached at 212/583-9700. Diane Wilkinson, a market analyst at InMedica (Wellingborough, UK), takes a look at key imaging segments that are being driven by proven clinical benefits and the trend toward portability. Wilkinson can be reached at +44 1933 402255 or via e-mail at [email protected].

Business Planning & Technology Development

Successful medtech companies understand the importance of a company's intellectual property portfolio in deriving an accurate valuation prior to a company acquisition. In "Building Acquisition Value with Intellectual Property", Scott Lloyd, an analyst with research and advisory firm Nerac Inc. (Tolland, CT) describes key considerations for determining and conveying the value of a medtech patent portfolio. Lloyd, an attorney registered with the U.S. Patent and Trademark Office, has several years of academic and industry experience in biotechnology and pharmaceuticals. He has published and presented on various scientific and intellectual property topics, and assists companies across multiple disciplines in developing strategies for research, patenting, licensing, and acquisitions. He can be reached at 860/872-7000 or via e-mail at [email protected].

Governmental & Legal Affairs

On December 4, 2007, the U.S. Supreme Court heard oral arguments in Riegel v. Medtronic Inc. The Court's much-anticipated decision—expected in July 2008—should provide a definitive resolution to the issue of federal preemption for medical devices approved by FDA under the premarket approval path. In "Preemption's Day in Court", Caryn M. Silverman provides background on the series of events leading up to this decision—and what it could mean for medical device manufacturers. Silverman is a partner in the law firm of Sedgwick, Detert, Moran and Arnold LLP (New York City). She is an experienced trial and litigation attorney who has particular expertise in product liability, with an emphasis on pharmaceutical and medical device litigation. She can be reached at 212/422-0202 or via e-mail at [email protected].

Copyright ©2008 MX